The Quantity And Quality Of Worldwide New Drug Introductions, 1982–2003 | Zendy

Henry G. Grabowski | Zendy; Y. Richard Wang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The Quantity And Quality Of Worldwide New Drug Introductions, 1982–2003

Author(s) -

Henry G. Grabowski,

Y. Richard Wang

Publication year - 2006

Publication title -

health affairs

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.837

H-Index - 178

eISSN - 2694-233X

pISSN - 0278-2715

DOI - 10.1377/hlthaff.25.2.452

Subject(s) - orphan drug , microbiology and biotechnology , world class , quality (philosophy) , agricultural economics , business , economic growth , biology , economics , engineering , bioinformatics , philosophy , epistemology , industrial engineering

We examined trends in the introduction of new chemical entities (NCEs) worldwide from 1982 through 2003. Although annual introductions of NCEs decreased over time, introductions of high-quality NCEs (that is, global and first-in-class NCEs) increased moderately. Both biotech and orphan products enjoyed tremendous growth, especially for cancer treatment. Country-level analyses for 1993-2003 indicate that U.S. firms overtook their European counterparts in innovative performance or the introduction of first-in-class, biotech, and orphan products. The United States also became the leading market for first launch.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research